All In Biotech

Drug Trial Radar · NCT05050318

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Collection of Serum Samples From Children 6 Months to < 9 Years of Age Who Received Fluzone® Quadrivalent and Adults ≥ 65 Years of Age Who Received Fluzone® High-Dose Quadrivalent, Influenza Vaccines, 2021-2022 Formulations

Last checked: Nov 20, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

90

Actual

Start

Sep 8, 2021

Primary completion

Nov 10, 2021

Study completion Nov 10, 2021

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Sep 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a phase IV, multi-center, open-label study. The study collected serum samples from children 6 months to less than (\<) 9 years of age who received Fluzone Quadrivalent vaccine and adults greater than or equal to (\>=) 65 years of age who received Fluzone High-Dose Quadrivalent vaccine for submission to CBER to aid in the influenza vaccine strain selection process.

Conditions

  • Influenza Immunization
  • Healthy Volunteers

Interventions

  • Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulationBiological

    Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)

  • Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulationBiological

    Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Aged 6 Months to <9 Years Who Provided Serum Samples for Analysis: Groups 1 and 2Time frame: Visit 1 (Day 1; pre-vaccination) and 28 days post-final vaccination at Visit 2 (for participants with 1 vaccination)/Visit 3 (for participants with 2 vaccination)
  2. Number of Participants Aged >=65 Years Who Provided Serum Samples for Analysis: Group 3Time frame: Visit 1 (Day 1; pre-vaccination) and 21 days post-vaccination (Visit 2)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number :8400001

    Bardstown, Kentucky

  • Investigational Site Number :8400002

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.